Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Outcomes of high-risk acute promyelocytic leukemia patients treated with arsenic trioxide (ATO)/all trans retinoic acid (ATRA) based induction and consolidation without maintenance phase: A case SeriesHematology/Oncology and Stem Cell Therapy.  13:143-146. 2020
2020 Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors 2020
2020 Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyJournal for ImmunoTherapy of Cancer.  8. 2020
2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow ResultsClinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
2019 Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancy 2019
2019 Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionBlood.  134:48. 2019
2019 Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphomaBritish Journal of Haematology.  184:674-676. 2019
2019 Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the LiteratureCase Reports in Oncology.  12:260-276. 2019
2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experienceLeukemia Research.  75:29-35. 2018
2018 All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisisLeukemia Research Reports.  10:16-19. 2018
2017 Treatment of Relapsed/Refractory Acute Myeloid LeukemiaCurrent Treatment Options in Oncology.  18. 2017
2017 Dexrazoxane for cardioprotection in older adults with acute myeloid leukemiaLeukemia Research Reports.  7:36-39. 2017
2017 Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Case Reports in Hematology.  2017:9681832. 2017
2016 VEGF inhibitors in renal cell carcinoma 2016
2016 Spotlight on pembrolizumab in non-small cell lung cancer: The evidence to dateOncoTargets and Therapy.  9:5855-5866. 2016
2016 Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML.Case Reports in Hematology.  2016:1259759. 2016
2014 Remission of rheumatoid arthritis on brentuximab vedotinRheumatology.  53:2314-2315. 2014
2014 Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AMLPhysiological Genomics.  46:448-456. 2014
2014 Isolated gastric myeloid sarcoma: a case report and review of the literature.Case Reports in Hematology.  2014:541807. 2014
2011 Obesity and low vision as a result of excessive Internet use and television viewingInternational Journal of Food Sciences and Nutrition.  62:60-62. 2011
2010 Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children?Journal of Child Health Care.  14:375-385. 2010

Chapter

Year Title Altmetric
2014 Can we cure CML without transplantation?.  279-326. 2014

Research Overview

  • Dr Vachhani’s primary interest is in hematological malignancies, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). His specific research interests include developmental therapeutics and clinical trials for high-risk, elderly and relapsed AML.
  • Principal Investigator On

  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by FORTY SEVEN, INC. 2020 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by AMGEN, INC. 2019 - 2023
  • Private Grant  awarded by ABBVIE INC 2019 - 2023
  • Private Grant  awarded by CTI BIOPHARMA CORP 2020 - 2022
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC 2020 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2020 - 2021
  • Investigator On

  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University 2020 - 2025
  • Private Grant  awarded by JUNO THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by TG THERAPEUTICS 2019 - 2024
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2019 - 2024
  • Private Grant  awarded by SUTRO BIOPHARM 2020 - 2024
  • Private Grant  awarded by KITE PHARMA 2019 - 2024
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2019 - 2024
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2019 - 2024
  • Private Grant  awarded by RHIZEN PHARMACEUTICALS SA 2018 - 2023
  • Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease, BMT CTN PROTOCOL #1507  awarded by National Marrow Donor Program 2017 - 2023
  • Private Grant  awarded by JUNO THERAPEUTICS 2020 - 2023
  • Private Grant  awarded by ASTEX PHARMACEUTICALS 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2020 - 2023
  • Private Grant  awarded by INCYTE CORPORATION 2017 - 2022
  • Private Grant  awarded by GlaxoSmithKline 2019 - 2022
  • Private Grant  awarded by FORTY SEVEN, INC. 2018 - 2022
  • Private Grant  awarded by INNATE PHARMA 2020 - 2022
  • Private Grant  awarded by INCYTE CORPORATION 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS 2019 - 2021
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2019
  • Private Grant  awarded by ONO PHARMACEUTICAL COMPANY LTD 2019
  • Private Grant  awarded by IMMUNOGEN, INC. 2018 - 2019
  • Private Grant  awarded by AMGEN, INC. 2018 - 2019
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2017
  • Education And Training

  • Doctor of Medicine, 2012
  • Full Name

  • Pankit Vachhani